Read by QxMD icon Read

Sjogren Syndrome

shared collection
15 papers 0 to 25 followers
C Ballester, V Grobost, P Roblot, O Pourrat, F Pierre, H Laurichesse-Delmas, D Gallot, Y Aubard, H Bezanahary, A-L Fauchais
OBJECTIVES: Primary Sjögren's syndrome (pSS) is one of the most common autoimmune diseases, mainly affecting women during the fourth decade of life. During pregnancy, the presence of anti-Ro/SSa and anti-La/SSb antibodies increases the risk of congenital heart block (CHB). Foetal and pregnancy outcomes in pregnant women with pSS compared with the general population are difficult to evaluate because of confounding factors including age and body mass index (BMI). METHOD: The aim of this case-control study was to analyse the impact of pSS in pregnant women on foetal and pregnancy outcomes...
May 18, 2016: Scandinavian Journal of Rheumatology
F Roca, S Dominique, J Schmidt, A Smail, P Duhaut, H Lévesque, I Marie
Interstitial lung disease (ILD) has been reported in 3 to 11% of patients with primary Sjögren's syndrome (pSS). The aims of this retrospective multicenter study were to: 1) analyze characteristics and outcome of ILD in pSS; and 2) evaluate predictive factors associated with ILD onset and deterioration. Twenty-one of 263 patients with pSS (8%) developed ILD. ILD onset preceded pSS diagnosis (n=5), was concurrently identified in association with pSS (n=6) and developed after pSS onset (n=9). Presenting ILD manifestations were: acute/subacute (n=11) onset of ILD, symptomatic progressive onset of ILD (n=5), and asymptomatic patients exhibiting abnormalities consistent with ILD on PFTs and HRCT-scan (n=5)...
September 25, 2016: Autoimmunity Reviews
Ming-Han Chen, Chun-Ku Chen, Hsiao-Ping Chou, Ming-Huang Chen, Chang-Youh Tsai, Deh-Ming Chang
OBJECTIVES: Interstitial lung disease (ILD) is one of the major systemic manifestations of primary Sjögren's syndrome (pSS). The aim of this study was to evaluate the therapeutic effect of rituximab on pSS patients with ILD. METHODS: Pulmonary function test results, including diffusing capacity for carbon monoxide (DLCO) and DLCO/alveolar volume (Va) ratio, and high-resolution computed tomography (HRCT) findings/scores in ten pSS patients with ILD treated with rituximab were retrospectively investigated...
August 31, 2016: Clinical and Experimental Rheumatology
Sarah Lechtman, Marie-Pierre Debray, Bruno Crestani, Catherine Bancal, Muriel Hourseau, Antoine Dossier, Jean-François Alexandra, Marie-Paule Chauveheid, Thomas Papo, Karim Sacre
OBJECTIVES: To analyze the prevalence, characteristics and outcome of cystic lung disease associated with Sjögren's syndrome (SS). METHODS: From June 2010 to February 2015, 90 consecutive SS patients [60.1±14.8years; 88 (97.8%) female, 75 (83.3%) primary SS] had a systematic chest CT-scan. The presence of thin-walled cysts was analyzed by one experienced radiologist. Demographic data, clinical history, laboratory findings, and pulmonary function tests were extracted retrospectively from medical records...
September 19, 2016: Joint, Bone, Spine: Revue du Rhumatisme
Maureen Rischmueller, Joanna Tieu, Susan Lester
Primary Sjögren's syndrome (pSS) is a relatively common autoimmune systemic rheumatic disease. In addition to sicca syndrome and swollen salivary glands, systemic features manifest in the majority of patients, and are severe in 15%, particularly affecting the joints, skin, lungs, and peripheral nervous system. A recent meta-analysis estimated a pooled relative risk of 13.76 for the development of non-Hodgkin lymphoma, particularly in pSS patients who have parotid enlargement, vasculitis, cryoglobulinemia, and antibodies to Ro and La...
February 2016: Best Practice & Research. Clinical Rheumatology
Alain Saraux, Jacques-Olivier Pers, Valérie Devauchelle-Pensec
Primary Sjögren syndrome (pSS) is a progressive autoimmune disease characterized by sicca and systemic manifestations. In this Review, we summarize the available data on topical and systemic medications, according to clinical signs and disease activity, and we describe the ongoing studies using biologic drugs in the treatment of pSS. Expanding knowledge about the epidemiology, classification criteria, systemic activity scoring (ESSDAI) and patient-reported outcomes (ESSPRI) is driving active research. Treatment decisions are based on the evaluation of symptoms and extraglandular manifestations...
August 2016: Nature Reviews. Rheumatology
Steven E Carsons, Frederick B Vivino, Ann Parke, Nancy Carteron, Vidya Sankar, Richard Brasington, Michael T Brennan, William Ehlers, Robert Fox, Hal Scofield, Katherine M Hammitt, Julius Birnbaum, Stuart Kassan, Steven Mandel
OBJECTIVE: The Sjögren's Syndrome Foundation (SSF) Clinical Practice Guidelines (CPG) are designed to improve quality and consistency of care in Sjögren's by offering recommendations for management. METHODS: Management questions for the systemic manifestations of Sjögren's were posed by the CPG committee (CPGC) with input from patients and rheumatologists. Clinical questions were assigned to a topic review group (TRG) which performed systematic reviews, data extraction and drafted guidelines...
July 7, 2016: Arthritis Care & Research
Carlos D Martínez-Balzano, Sunkaru Touray, Scott Kopec
BACKGROUND: Cystic lung disease (CLD) in Sjögren syndrome (SS) is a condition with unclear prognostic implications. Our objectives in this study are to determine its frequency, progression over time, and associated risk factors and complications. METHODS: Eighty-four patients with primary or secondary SS and chest imaging, chest radiograph, or CT scan were retrospectively evaluated for CLD. Thirteen patients with cysts were found. Baseline characteristics of all patients were collected...
September 2016: Chest
Francine Bertolais do Valle Souza, Gustavo José Martiniano Porfírio, Brenda Nazaré Gomes Andriolo, Julia Vajda de Albuquerque, Virginia Fernandes Moça Trevisani
BACKGROUND: Primary Sjögren's Syndrome (pSS) is a systemic autoimmune disease that involves the exocrine glands and internal organs. pSS leads to destruction and loss of secretory function due to intense lymphoplasmacytic infiltration. Therapeutic options include mainly symptomatic and supportive measures, and traditional immunosuppressant drugs have shown no effectiveness in randomized trials. Rituximab (RTX) is a chimeric antibody anti-CD20 that leads to B cell depletion by diverse mechanisms...
2016: PloS One
Andreas V Goules, Athanasios G Tzioufas
Primary Sjӧgren's syndrome (pSS) is a complex autoimmune disease with distinct clinical phenotypes and variable outcomes. The systemic form of the disease is characterized by immune complex mediated manifestations and is complicated by lymphoma as a result of a polyclonal B cell hyperactivity that is evolving into B cell malignancy. In the past decades, well-established clinical and serological markers have been described in the literature to identify high-risk patients and to predict lymphoma development...
July 2016: Autoimmunity Reviews
Gianni Masi, Pasquale Annunziata
No abstract text is available yet for this article.
May 2016: Autoimmunity Reviews
G Nocturne, A Virone, Wan-Fai Ng, V Le Guern, E Hachulla, D Cornec, C Daien, O Vittecoq, B Bienvenu, C Marcelli, D Wendling, Z Amoura, R Dhote, C Lavigne, R Fior, J E Gottenberg, R Seror, X Mariette
OBJECTIVE: To define parameters predictive of lymphoma development in patients with primary Sjögren's syndrome (SS). METHODS: A multicenter case-control survey was performed to identify predictors of lymphoma. Cases were patients who developed lymphoma after diagnosis of primary SS and were mainly recruited through the Club Rhumatismes et Inflammation network. For each case, 2 controls (matched for disease duration and age) were randomly selected among patients with primary SS and without lymphoma...
April 2016: Arthritis & Rheumatology
Luca Quartuccio, Chiara Baldini, Elena Bartoloni, Roberta Priori, Francesco Carubbi, Laura Corazza, Alessia Alunno, Serena Colafrancesco, Nicoletta Luciano, Roberto Giacomelli, Roberto Gerli, Guido Valesini, Stefano Bombardieri, Salvatore De Vita
OBJECTIVE: This study aims to compare clinical and laboratory features of patients who, while satisfying the American European Consensus Group (AECG) criteria for primary Sjögren's syndrome (SS), do not present the positivity for anti-Ro/SSA and/or anti-La/SSB, with patients that meet the AECG criteria and are positive for anti-Ro/SSA and/or anti-La/SSB. METHODS: 548 patients were selected based on the following criteria, and exclusion of patients negative for histopathology but positive for anti-Ro/SSA and anti-La/SSB: 1...
November 2015: Autoimmunity Reviews
Benjamin A Fisher, Rachel M Brown, Simon J Bowman, Francesca Barone
Salivary gland changes, characterised by a focal lymphocytic sialadenitits, play an important role in the diagnosis of primary Sjögren's syndrome (PSS) and were first described over 40 years ago. Recent evidence suggests that minor salivary gland biopsy may also provide information useful for prognostication and stratification, yet difficulties may arise in the histopathological interpretation and scoring, and evidence exists that reporting is variable. With the increasing number of actual and proposed clinical trials in PSS, we review the evidence that might support the role of histopathology as a biomarker for stratification and response to therapy and highlight areas where further validation work is required...
September 2015: Annals of the Rheumatic Diseases
Aristea Papageorgiou, Michael Voulgarelis, Athanasios G Tzioufas
The intrinsic and complex nature of primary Sjӧgren's syndrome (pSS) makes it difficult to identify risk factors that can predict the development and outcome of non-Hodgkin's lymphoma (NHL), yet patients at high risk for such complication seem to bear certain clinic-serological characteristics that render them a unique profile. In the last decade, research focusing on B-cell hyperactivity as the hallmark of pSS-related lymphoproliferation has shed light on certain biological and molecular factors that participate in disease evolution and lymphoma development, thus indicating possible predictors of lymphoma development and outcome...
July 2015: Autoimmunity Reviews
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"